Philips announces new milestones in the development of the world’s first spectral detector angio CT solution

Royal Philips announced new milestones in the development of the world’s first spectral detector angio CT solution – Philips Spectral Angio CT suite* – bringing the company’s breakthrough spectral CT imaging technology into an integrated hybrid angio CT suite.

By combining its award-winning Spectral CT 7500 system and its Image Guided Therapy System – Azurion with FlexArm – in a fully integrated interventional suite solution, Philips aims to give physicians immediate access to these two key imaging modalities in a single room, enabling innovation in minimally-invasive procedures in areas such as oncology, stroke, and trauma care.

Leiden University Medical Center has joined Philips’ global network of clinical partners to investigate how its spectral detector angio CT solution could potentially offer new treatment opportunities and improve patient care.

Other leading clinical institutes that Philips is working with on this innovation are Mayo Clinic and Baptist Health’s Miami Cardiac & Vascular Institute.

Philips Spectral Angio CT suite combines the company’s latest diagnosis and treatment technologies. Philips Image Guided Therapy System – Azurion with FlexArm – is the company’s next-generation image-guided therapy platform, integrating best-in-class imaging systems, software, and specialized diagnostic and therapeutic devices to support exceptional treatment for the most complex procedures. The addition of Philips’ award-winning Spectral CT 7500 system means physicians only need one scan to capture all the spectral information required to differentiate and quantify different tissues. Spectral CT enables improved detection, delineation, and quantification of lesions, leading to better-informed planning for minimally-invasive procedures and more precise interventions. It has already proved its worth in other areas of oncology – for example, it has demonstrated higher sensitivity in detecting malignant findings and improved readings of incidental findings. With its ability to improve tissue characterization, the Spectral CT 7500 offers significant benefits over conventional CT.

Through continuous research, Philips is building clinical evidence that supports the added value of spectral CT imaging for diagnosis and treatment guidance.

At this year’s Cardiovascular and Interventional Radiological Society of Europe Annual Meeting a presentation is being given by Filippo Piacentino, interventional radiologist at the University of Insubria, on the value of spectral CT imaging guidance for performing high-confidence tumor biopsies. The results being presented illustrate the potential for Philips’ spectral CT technology to better guide biopsies by distinguishing between active and non-active regions in a tumor. Ensuring that a biopsy contains a high number of actively dividing cancer cells is important for a high-confidence diagnosis.

Philips also announced a research collaboration with the University of Pennsylvania to study the practicality of using spectral CT-based tissue temperature mapping to provide real-time feedback during tumor thermal ablation procedures to confirm its effectiveness before the patient leaves the room. This will potentially reduce the risk of localized tumor recurrence.

Announcing these important milestones in the development of our unique Philips Spectral Angio CT suite shows our strong commitment and progress in co-creating the future of image-guided therapy. By combining the best of our award-winning modalities into a single suite we aim to unlock new treatment approaches that could benefit both patients and their physicians.

Karim Boussebaa, General Manager of Image Guided Therapy Systems at Philips